A GLP-1/glucagon dual agonist induced significant weight loss and improved multiple cardiometabolic parameters for adults ...

As Pfizer acquires MET-097 maker Metsera, phase 2 data show potential for greater tolerability and once-monthly dosing.

VIENNA — Adults with obesity but without diabetes who took the investigational, oral GLP-1 receptor agonist orforglipron for 72 weeks lost significantly more weight than those on placebo, according to ...

This is read by an automated voice. Please report any issues or inconsistencies here. If you’ve injected your weight-loss medication in an airport bathroom, you’re not alone. Or maybe you decided to ...

Microdosing GLP-1 weight loss drugs like semaglutide is trendy, with supporters touting benefits such as lower costs and potentially fewer side effects. But some doctors are skeptical, calling it ...

Share on Pinterest The “golden dose” left in Mounjaro or Ozempic pens may do more harm than good, according to experts. Design by MNT; Photography by Bloomberg/Getty Images Over the last few years, ...

BEIJING, Sept. 18, 2025 /PRNewswire/ -- Beijing QL Biopharmaceutical Co., Ltd. (hereafter "QL Biopharm" or the "company") announced today at the European Association for the Study of Diabetes (EASD) ...

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...

Andy Cohen is admitting to dabbling in the world of weight loss drugs. The "Real Housewives" executive producer opened up about "micro-dosing" on an unnamed GLP-1 weight loss drug on his SiriusXM ...